Nektar Therapeutics

NKTR Healthcare Biotechnology

Nektar Therapeutics' revenue for fiscal 2025 (year ended December 2025) was $55.2 million, down 43.9% from fiscal 2024. In the quarter to June 2026, revenue fell 9.34%, EPS grew 58.3% and free cash flow fell 65.7%, each against the same quarter a year earlier.

35.78 1.94 −5.14%
Market cap
$1.3B
P/E
0.0×
Fwd P/E
−6.3×
Dividend yield
—
F-score
3/9
Altman Z
−17.07
Beneish M
n/a
Dividend safety
n/a
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Piotroski F-Score
3 5 8 2 5 2 4 3 4 3
P/E ratio
0.00 0.00 8.35 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
10.71 29.23 4.67 32.98 19.86 24.31 4.45 1.24 1.94 12.91
Altman Z-Score
(2.45) 8.31 9.18 2.62 1.83 (0.62) (6.38) (13.11) (16.13) (17.07)
P/FCF ratio
0.00 0.00 7.89 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(8.64) (10.65) 8.30 1.55 0.06 (5.15) (12.71) (27.81) (36.33) (41.60)
P/Operating CF
(33.82) (111.88) (47.45) (30.19) (30.79) (16.35) (7.11) (2.38) (4.14) (10.98)
Beneish M-Score
(3.04) (2.27) 1.54 2.35 (2.73) (3.39) (3.82) (4.39) — —
P/B ratio
20.11 102.42 3.25 2.69 2.82 3.65 1.12 0.86 3.15 7.94
Price to Tangible BV
152.48 794.14 3.40 2.84 3.04 4.11 1.41 2.06 0.00 8.42
EV/Sales
10.59 29.47 3.87 25.79 16.20 22.04 4.43 3.45 4.45 17.56
EV/EBITDA
0.00 0.00 6.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
(14.97) (112.78) 6.42 (8.99) (7.91) (5.44) (1.34) (1.61) (2.50) (4.65)
EV/FCF
(14.19) (100.67) 6.53 (8.33) (7.73) (5.25) (1.37) (1.62) (2.47) (4.65)
Quick Ratio
5.60 5.36 16.81 3.85 9.51 8.88 7.49 5.95 4.16 4.59
Current Ratio
5.90 5.82 17.53 4.02 9.83 9.34 8.00 6.45 4.26 4.97
Net Debt/EBITDA
1.46 1.13 (1.56) 2.45 2.58 1.70 1.39 1.69 2.53 1.77
Debt/Assets
43.33% 48.19% 11.49% 12.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
2.80 2.79 0.14 0.18 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
0.31 0.57 0.90 0.06 0.09 0.08 0.10 0.16 0.28 0.19
Operating CF/Net income
0.76 0.83 1.05 0.75 0.70 0.79 0.83 0.70 1.48 1.27
Capex/Depreciation
(0.42) (0.66) (1.07) (14.92) (0.51) (1.06) 0.58 0.00 (0.33) (0.17)
Interest Coverage
(2.68) (1.46) 16.08 (9.49) (11.45) (9.43) (13.01) (10.41) (3.74) (5.35)
ROE
(324.73%) (109.91%) 75.47% (28.22%) (35.80%) (59.64%) (70.39%) (110.95%) (124.10%) (217.94%)
ROA
(28.76%) (17.94%) 51.25% (21.35%) (25.28%) (39.45%) (40.29%) (49.80%) (33.90%) (56.17%)
ROIC
0.00% (101.01%) 68.34% (82.49%) (1,725.40%) 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(36.61%) (30.39%) 48.51% (38.88%) (41.08%) (67.95%) (72.17%) (92.55%) (58.51%) (76.39%)
Average Days of Receivables
34.59 5.95 13.22 117.20 92.83 80.56 23.71 4.88 0.00 0.00
Research and Development Expense of Revenue
123.19% 87.24% 33.48% 379.15% 267.26% 392.78% 237.17% 126.67% 122.84% 212.43%
Selling, General and Administrative Expense of Revenue
26.76% 17.02% 6.82% 86.12% 68.46% 120.55% 100.30% 85.90% 77.98% 124.34%
Intangible Assets out of Total Assets
0.13 0.15 0.04 0.04 0.05 0.07 0.11 0.00 0.00 0.00
Share Based Compensation of Revenue
15.63% 11.90% 7.38% 87.07% 61.64% 92.90% 62.27% 37.05% 21.96% 22.90%
Graham Net Nets
(0.03) (0.01) 0.18 0.22 0.22 0.14 0.49 0.57 0.10 0.11
Graham Number
0.00 0.00 449.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
(8.66%) (1.09%) 11.98% (11.62%) (14.64%) (21.16%) (89.91%) (247.34%) (63.41%) (24.12%)
Free Cash Flow Yield
(6.96%) (1.00%) 12.67% (9.39%) (10.55%) (17.26%) (72.31%) (171.39%) (92.63%) (29.26%)
Revenue per Share
17.77 29.58 105.49 9.82 12.84 8.34 7.38 7.11 7.18 3.27
Operating CF per Share
(12.57) (7.73) 63.49 (28.16) (26.30) (33.75) (24.36) (15.20) (12.82) (12.36)
Capex per Share
(0.69) (0.93) (1.03) (2.25) (0.61) (1.23) 0.60 0.03 (0.11) (0.01)
Free Cash Flow per Share
(13.25) (8.66) 62.46 (30.41) (26.91) (34.98) (23.75) (15.17) (12.92) (12.37)
Cash per Share
41.79 28.47 118.04 113.51 89.15 60.03 40.46 23.96 18.61 14.57
Shareholders Equity per Share
9.46 8.44 151.83 120.41 90.44 55.58 29.37 10.34 4.43 5.32
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
9.46 8.44 151.83 120.41 90.44 55.58 29.37 10.34 4.43 5.32
Free Cash Flow
(123.42) (90.09) 706.61 (354.97) (320.54) (427.65) (296.49) (192.23) (177.18) (208.68)
Working Capital
353.73 270.66 1,355.69 1,067.66 1,022.23 710.38 477.76 279.43 199.89 212.73
Capital Expenditures
(6.39) (9.68) (11.61) (26.28) (7.26) (14.99) 7.52 0.38 (1.47) (0.17)
Net Current Asset Value
(54.79) (94.22) 1,005.09 849.59 676.53 357.90 202.01 63.66 18.18 75.69
EV/EBIT
0.00 0.00 6.71 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
0.04 0.03 0.01 0.23 0.05 0.15 (0.08) 0.00 0.01 0.00
Price to Operating Income
0.00 0.00 8.11 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
0.23 0.31 0.22 0.03 0.24 0.23 0.40 4.47 1.29 0.50
Cash ROIC
(17.05%) (14.32%) 21.41% (11.90%) (14.98%) (30.26%) (34.02%) (44.23%) (56.08%) (62.18%)
Accounts Receivable Turnover
9.29 29.74 49.49 2.86 4.04 3.32 6.47 25.08 0.00 0.00
Accounts Payable Turnover
11.67 8.04 4.59 1.70 0.94 1.56 1.90 2.96 2.87 0.00
Inventory Turnover
2.69 2.80 2.21 1.78 1.39 1.60 1.24 1.91 0.00 —
Average Days of Payables
34.02 57.14 87.53 328.46 414.89 142.89 218.98 106.45 137.50 0.00
Days of Inventory on Hand
134.20 128.16 170.16 216.28 286.57 231.65 323.95 174.04 0.00 —
Average Receivables
17.81 10.35 24.11 40.01 37.85 30.69 14.24 3.59 — —
Average Payables
2.59 3.80 5.32 12.54 20.69 15.94 11.36 11.41 10.70 11.17
Average Inventory
11.23 10.92 11.05 12.02 13.98 15.55 17.50 17.65 — —
Average Assets
533.76 538.87 1,329.52 2,063.76 1,758.06 1,327.98 913.89 554.32 350.94 292.13
Average Common Equity
47.28 87.98 902.70 1,561.48 1,241.34 878.40 523.07 248.81 95.86 75.28

Fold the line items

Columns are period end dates